Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer

The prolonged contagious period after viral infection in immunocompromised patients may affect how long precautions will be necessary to reduce further transmission. Replication-competent SARS-CoV-2 was detected for up to 61 days in patients who were immunocompromised by treatment for cancer.

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 383; no. 26; pp. 2586 - 2588
Main Authors Aydillo, Teresa, Gonzalez-Reiche, Ana S, Aslam, Sadaf, van de Guchte, Adriana, Khan, Zenab, Obla, Ajay, Dutta, Jayeeta, van Bakel, Harm, Aberg, Judith, García-Sastre, Adolfo, Shah, Gunjan, Hohl, Tobias, Papanicolaou, Genovefa, Perales, Miguel-Angel, Sepkowitz, Kent, Babady, N. Esther, Kamboj, Mini
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 24.12.2020
Subjects
Adult
Aged
Cancer therapies
Coronaviruses
Correspondence
COVID-19
COVID-19 - complications
COVID-19 - virology
Disease transmission
Female
Genomes
Hematopoietic Stem Cell Transplantation
Humans
Immunocompromised hosts
Immunosuppression
Immunosuppressive agents
Influenza
Male
Middle Aged
Neoplasms - complications
Neoplasms - therapy
Patients
Philanthropy
Severe acute respiratory syndrome coronavirus 2
Transplants & implants
Virus Shedding
Online AccessGet full text

Cover

More Information
Summary:The prolonged contagious period after viral infection in immunocompromised patients may affect how long precautions will be necessary to reduce further transmission. Replication-competent SARS-CoV-2 was detected for up to 61 days in patients who were immunocompromised by treatment for cancer.
Bibliography:SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
content type line 14
ObjectType-Article-2
content type line 23
Drs. Babady and Kamboj contributed equally to this letter.
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMc2031670